US senators unveil bill to prevent easing of curbs on Nvidia chip sales to China

A bipartisan group of U.S. senators filed the SAFE CHIPS Act to block the Trump administration from loosening export rules for 30 months (2.5 years), requiring the Commerce Department to deny any license requests for U.S. AI chips more advanced than currently allowed to buyers in China, Russia, Iran and North Korea and to brief Congress a month before any proposed rule changes. The measure, co-sponsored by senators including Pete Ricketts and Chris Coons and backed by China hawks such as Tom Cotton, directly targets potential sales of advanced Nvidia and AMD AI chips (including reports around Nvidia’s H200) and could materially constrain near-term revenue opportunities for U.S. chipmakers while intensifying U.S.-China tech and rare-earth trade tensions.

Analysis

Market structure: The SAFE CHIPS bill crystallizes a 30-month blackout for cutting-edge U.S. AI GPUs into China, shrinking the addressable market for Nvidia (NVDA) and to a lesser extent AMD (AMD) in the near term. Expect export-constrained premium pricing power in non-China markets but a 5–15% revenue hit potential for NVDA over 12 months if China demand (~mid-teens of GPU demand) is excluded; Chinese domestic suppliers and cloud providers are clear long-term beneficiaries.

Risk assessment: Tail risks include a permanent broader export regime (beyond 30 months), Chinese countermeasures on rare earths or accelerated indigenous GPU/AI-accelerator builds, and inverted supply-chain costs raising gross margins pressure for fabless vendors. Market reaction will be immediate (days) with elevated vol for NVDA/AMD, medium-term guidance revisions in next 1–3 quarters, and strategic decoupling effects materializing over 2–3 years.

Trade implications: Relative-value favors AMD over NVDA given sentiment asymmetry and lower perceived dependency on top-tier H200-class chips; semiconductor equipment and domestic cloud-capex suppliers (AMAT, LRCX, INTC capex beneficiaries) are probable beneficiaries on 6–12 month view. Use options to express directional and volatility views—buy protective puts on NVDA and consider call overwrites on AMD or SMH to harvest carry while waiting for clarity.

Contrarian angles: Consensus assumes permanent lost China revenue; that may be overdone—waivers, carve-outs for cloud providers, or diplomatic deals could re-open flows within 6–12 months and trigger sharp rebounds (30%+ move) in NVDA. Conversely, blocking sales accelerates Chinese silicon roadmaps, so a two-year defensive posture and tech-cycle rotation into equipment and non-China software/IP is prudent.

Key Decisions for Investors

• Establish a 2–3% long position in AMD (AMD) vs a 2–3% short position in NVDA (NVDA) by notional size (pair trade) for a 3–6 month horizon to capture relative rerating if NVDA guidance is cut; rebalance if spread narrows/gaps >15%.
• Buy 3-month NVDA 5–10% OTM puts sized to 1–2% of portfolio as insurance against a 15–30% downside on a bill passage or negative guidance; roll or sell if bill fails to pass within 60 days.
• Add 1–2% positions in semiconductor equipment (AMAT, LRCX) over 6–12 months to play domestic capex uplift; trim if order-book surprises are negative for two consecutive quarters or if China revenue risk subsides.
• Trim direct China-facing hardware/cloud exposure by 20–40% (names with >15% revenue from China) and redeploy into software/IP/cloud services and US-focused fabs; restore exposure only after Commerce/ Congressional signals (briefings or vote) within 30–90 days.